Insmed (INSM) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenues reached $306.0 million, up 230% year-over-year, driven by the US launch of BRINSUPRI and continued ARIKAYCE growth, with BRINSUPRI generating $207.9 million and ARIKAYCE $98.1 million.

• BRINSUPRI achieved 44% sequential growth, maintained strong organic demand, and was approved in the US, EU, and UK, with regulatory submission accepted in Japan.

• ARIKAYCE posted year-over-year growth, with positive Phase 3b ENCORE results supporting label expansion filings in the US and Japan.

• TPIP advanced with four Phase 3 trials underway in PAH and PH-ILD, orphan drug designation, and positive physician feedback.

• Net loss narrowed to $163.6 million ($0.76 per share) from $256.6 million ($1.42 per share) in Q1 2025, reflecting improved operating leverage.

Financial highlights

• Net product revenues: $306.0 million (Q1 2026) vs. $92.8 million (Q1 2025), a 229.6% increase.

• BRINSUPRI global net revenues reached $207.9 million, up 44% sequentially from Q4 2025; ARIKAYCE Q1 2026 worldwide revenues were $98.1 million.

• Cost of product revenues was $47.4 million (15.5% of revenues), reflecting improved gross margin due to BRINSUPRI's contribution.

• R&D expenses rose to $209.5 million, and SG&A expenses increased to $247.3 million, both reflecting expanded commercial and clinical activities.

• Cash, cash equivalents, and marketable securities totaled approximately $1.2 billion as of March 31, 2026.

Outlook and guidance

• Full-year 2026 revenue guidance for BRINSUPRI is at least $1 billion; ARIKAYCE guidance is $450 million to $470 million.

• Cash flow positivity is anticipated in 2027 without the need for additional capital, assuming no major business development expenses.

• Regulatory submissions for ARIKAYCE label expansion in the US and Japan are planned for H2 2026.

• Anticipates reporting data from TPIP PAH open-label extension in Q3 2026 and initiating additional Phase 3 studies for TPIP in PPF and IPF.

• Plans to submit one to two INDs per year from pre-clinical programs.